Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 19/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293213 | 0.84 | MAPK3 (0.72) | MAPK3MAPK1MAPK10MAPK9 | |
| SCHEMBL1323795 | 0.83 | MAPK3 (0.56) | MAPK3MAPK1MAPK10MAPK8MAPK9 | |
| SCHEMBL691377 | 0.80 | MAPK3 (0.80) | MAPK3MAPK1MAPK10MAPK9 | |
| SCHEMBL1559144 | 0.79 | MAPK3 (0.66) | MAPK3MAPK1MAPK10MAPK8MAPK9 | |
| SCHEMBL690795 | 0.78 | MAPK10 (0.57) | MAPK10MAPK8 | |
| SCHEMBL1557925 | 0.77 | MAPK3 (0.63) | MAPK3MAPK1MAPK10MAPK8MAPK9 | |
| SCHEMBL1559558 | 0.76 | MAPK3 (0.63) | MAPK3MAPK1MAPK10MAPK8MAPK9 | |
| SCHEMBL1559348 | 0.75 | MAPK1 (0.60) | MAPK3MAPK1MAPK10MAPK8MAPK9 | |
| SCHEMBL12103252 | 0.75 | MAPK1 (0.57) | MAPK3MAPK1 | |
| SCHEMBL1559217 | 0.74 | MAPK3 (1.00) | MAPK3MAPK1MAPK10MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | MAPK3 64/4885MAPK1 221/4885MAPK10 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.